pamrevlumab

FibroGen, Negative trial data, pamrevlumab, Duchenne muscular dystrophy

Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility

Anika Sharma

FibroGenā€™s troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...